Status:
UNKNOWN
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Lead Sponsor:
Austrian Migraine Registry Collaboration
Collaborating Sponsors:
Medical University of Vienna
Medical University Innsbruck
Conditions:
Migraine
Migraine With Aura
Eligibility:
All Genders
18+ years
Brief Summary
The present non-interventional study on migraine prevention with monoclonal CGRP antibodies adresses questions concering safety, swichting from one CGRP mab to another, efficacy on auras in the real w...
Detailed Description
Introduction: Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CGRP-R) are an effective option for the preventative treatment in episodic and chronic migraine. Al...
Eligibility Criteria
Inclusion
- Inclusion Criteria (all of the follwing)
- episodic or chronic migraine with or without aura
- erenumab, fremanezumab or galcanezumab is prescribed as a standard of care treatment by treating physician Eptinezumab may be included as soon as available in Austria.
- Exclusion Criteria:
- • Off label use of erenumab, fremanezumab or galcanezumab
Exclusion
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT05281770
Start Date
October 1 2022
End Date
December 1 2025
Last Update
October 20 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Innsbruck
Innsbruck, Tyrol, Austria, A6020
2
Medizinische Universität Wien
Vienna, Vienna, Austria, 1090
3
Clinic Hietzing
Vienna, Austria, A1130